Related Experiment Video
Updated: Aug 19, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Tenecteplase for the treatment of massive and submassive pulmonary embolism
Christoph Melzer1, Christoph Richter, Patrick Rogalla
1Medical Clinic, Charité Hospital, Schumannstrasse 20/21, D-10117 Berlin, Germany. christoph.melzer@charite.de
Background:
Data on thrombolytic therapy disclose benefits from thrombolytic therapy in patients with massive and submassive pulmonary embolism (PE). Previously published case reports have described the successful use of tenecteplase under these conditions.
Methods:
Four patients with massive and submassive PE received a weight-optimized dosing regimen of tenecteplase, administered as an intravenous bolus.
Results:
All patients experienced clinically relevant improvement of dyspnea following thrombus regression. Regression of right ventricular enlargement was documented in three cases. Tenecteplase was well tolerated and did not cause bleeding complications. Thirty-day mortality was zero.
Conclusions:
These data support the use of this new thrombolytic agent in patients with massive and submassive PE; however, sufficiently powered, randomized trials have not yet taken place for these indications.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Acute Coronary Syndrome I: Introduction